## NBIX: Neurocrine Biosciences, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.5% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($135.56)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Burney Co. Has $4.05 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX**
- Source: MarketBeat | 20251228T060944 | Somewhat-Bullish | Relevance: 100%
- Burney Co. significantly increased its stake in Neurocrine Biosciences (NASDAQ:NBIX) by 202.7% in Q3, now holding 28,825 shares valued at $4.05 million. Wall Street analysts maintain a "Moderate Buy" rating with a consensus price target of $175.25, and institutional investors own 92.59% of the company's stock. The company recently reported strong Q3 earnings, surpassing revenue and EPS estimates.

**2. Neurocrine Biosciences, Inc. $NBIX Shares Sold by Rice Hall James & Associates LLC**
- Source: MarketBeat | 20251227T120938 | Somewhat-Bullish | Relevance: 100%
- Rice Hall James & Associates LLC reduced its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 8.2% in the third quarter of 2025, selling 8,917 shares. Despite this, Neurocrine posted a strong Q3 performance, exceeding EPS and revenue expectations. Analysts remain largely bullish on NBIX, with several firms raising price targets and a consensus "Moderate Buy" rating.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | HC Wainwright & | $198 | $168 | +18% |
| 2025-12-12 | Mizuho | $175 | $146 | +20% |
| 2025-12-11 | Stifel | $188 | $183 | +3% |
| 2025-12-08 | RBC Capital | $180 | $160 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | HC Wainwright & | main | Buy |
| 2025-12-12 | Mizuho | main | Neutral |
| 2025-12-11 | Stifel | main | Buy |
| 2025-12-08 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 10 ($2.96M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 12.7% (-1.9%)
- Vanguard Group Inc: 9.7% (-1.0%)
- JPMORGAN CHASE & CO: 9.5% (+122.0%)
- Dodge & Cox Inc.: 5.6% (-0.2%)
- State Street Corpora: 4.4% (-2.7%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 5 raises (avg +13%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.27 indicates undervaluation relative to growth. Forward P/E 15.7x attractive for 33% earnings growth. Quality metrics strong (margin 16%). Balance sheet: strong liquidity (3.4x), low leverage (D/E 0.42). Analyst sentiment positive (5 raises, avg +13%). Insider selling cluster ($3.0M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.3B |
| Beta | 0.27 |
| 52W Range | $84.23 - $160.18 |
| Short Interest | 5.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.27 |
| Forward P/E | 15.7 |
| Current P/E | 20.8 |
| YoY Growth | 32.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -2.5% (minimal 5-day change). Below STRENGTH zone by 5.5pp (needs >3.0% for momentum thesis). Underperforming sector by 3.5pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-0.96), momentum weakening. RSI neutral at 42. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.55% (CS: 11) | Weak |
| RSI_14 | 42.2 | Neutral |
| MACD Histogram | -0.96 | Bearish |
| vs SMA20 | 0.958x | Below |
| vs SMA50 | 0.979x | Below |
| vs SMA200 | 1.100x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $143.64
- **Stop Loss:** $135.56 (5.6% risk)
- **Target:** $151.72 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 170
- **Position Value:** $24,418.80
- **Portfolio %:** 24.42%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-02-05 (Est: $2.41)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.07 | $2.17 | +4.9% |
| 2025Q2 | $1.50 | $1.65 | +9.6% |
| 2025Q1 | $1.09 | $0.70 | -36.0% |
| 2024Q4 | $1.93 | $1.69 | -12.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*